Literature DB >> 11489829

AKT-1, -2, and -3 are expressed in both normal and tumor tissues of the lung, breast, prostate, and colon.

M J Zinda1, M A Johnson, J D Paul, C Horn, B W Konicek, Z H Lu, G Sandusky, J E Thomas, B L Neubauer, M T Lai, J R Graff.   

Abstract

PURPOSE: The AKT/PKB kinase controls many of the intracellular processes that are dysregulated in human cancer, including the suppression of apoptosis and anoikis and the induction of cell cycle progression. Three isoforms of AKT have been identified: AKT-1, -2, and -3. Selective up-regulation of AKT-3 RNA expression has been reported in hormone-independent breast and prostate cancer cell lines suggesting that AKT-3 expression may be increased with breast or prostate tumor progression. To determine whether AKT-3 RNA expression is selectively up-regulated in human cancers and whether the patterns of AKT RNA expression may change with tumor development, we examined AKT isoform expression by RT-PCR in human cancer cell lines, primary human cancers, and normal human tissues. EXPERIMENTAL
DESIGN: AKT-1, -2, and -3 RNA expression was examined by RT-PCR. Because up-regulated AKT-3 expression has been implicated in human breast and prostate cancer progression, we also examined AKT-3 expression levels by semiquantitative RT-PCR using matched normal/tumor first-strand cDNA pairs from colon, breast, prostate, and lung cancers.
RESULTS: Our data reveal that the overwhelming majority of both normal and tumor tissues express all three of the AKT isoforms. Moreover, semiquantitative RT-PCR of matched normal/tumor pairs confirmed similar AKT-3 RNA expression levels in both normal and tumor tissue.
CONCLUSIONS: Our data show that both normal and tumor tissues express all three of the AKT isoforms and indicate that tumorigenesis does not involve a dramatic shift in the RNA expression patterns of the three AKT isoforms.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11489829

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  39 in total

Review 1.  Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape.

Authors:  Margrith E Mattmann; Sydney L Stoops; Craig W Lindsley
Journal:  Expert Opin Ther Pat       Date:  2011-06-02       Impact factor: 6.674

Review 2.  Targeting the PI3-kinase/Akt/mTOR signaling pathway.

Authors:  Burhan Hassan; Argun Akcakanat; Ashley M Holder; Funda Meric-Bernstam
Journal:  Surg Oncol Clin N Am       Date:  2013-08-06       Impact factor: 3.495

3.  The actin-bundling protein palladin is an Akt1-specific substrate that regulates breast cancer cell migration.

Authors:  Y Rebecca Chin; Alex Toker
Journal:  Mol Cell       Date:  2010-05-14       Impact factor: 17.970

4.  Grape Seed Proanthocyanidin Extract Ameliorates Streptozotocin-induced Cognitive and Synaptic Plasticity Deficits by Inhibiting Oxidative Stress and Preserving AKT and ERK Activities.

Authors:  Wei-Li Gao; Xiang-Hua Li; Xin-Peng Dun; Xiao-Kuan Jing; Ke Yang; Yan-Kun Li
Journal:  Curr Med Sci       Date:  2020-07-17

5.  Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance.

Authors:  Eric Wehrenberg-Klee; N Selcan Turker; Pedram Heidari; Benjamin Larimer; Dejan Juric; José Baselga; Maurizio Scaltriti; Umar Mahmood
Journal:  J Nucl Med       Date:  2016-04-14       Impact factor: 10.057

6.  rSW-seq: algorithm for detection of copy number alterations in deep sequencing data.

Authors:  Tae-Min Kim; Lovelace J Luquette; Ruibin Xi; Peter J Park
Journal:  BMC Bioinformatics       Date:  2010-08-18       Impact factor: 3.169

7.  Akt2 inhibition enables the forkhead transcription factor FoxO3a to have a repressive role in estrogen receptor alpha transcriptional activity in breast cancer cells.

Authors:  Catia Morelli; Marilena Lanzino; Cecilia Garofalo; Pamela Maris; Elvira Brunelli; Ivan Casaburi; Stefania Catalano; Rosalinda Bruno; Diego Sisci; Sebastiano Andò
Journal:  Mol Cell Biol       Date:  2009-11-23       Impact factor: 4.272

Review 8.  Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.

Authors:  Jaclyn LoPiccolo; Gideon M Blumenthal; Wendy B Bernstein; Phillip A Dennis
Journal:  Drug Resist Updat       Date:  2007-12-31       Impact factor: 18.500

9.  Effect of Akti-2 on sperm motility, capacitation and acrosome reaction in a mouse model.

Authors:  Yanmei Quan; Qiang Liu
Journal:  Biomed Rep       Date:  2016-03-07

10.  A splice variant of HER2 corresponding to Herstatin is expressed in the noncancerous breast and in breast carcinomas.

Authors:  Triantafyllia Koletsa; Ioannis Kostopoulos; Elpida Charalambous; Barbara Christoforidou; Eleni Nenopoulou; Vassiliki Kotoula
Journal:  Neoplasia       Date:  2008-07       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.